CEGID
13.6.2022 16:02:10 CEST | Business Wire | Press release
Cegid, a leading provider of cloud business management solutions for finance (treasury, tax, ERP), human resources (payroll, talent management), CPAs, retail and entrepreneurial sectors announces the acquisition of StorIQ, a London-based company with a staff of about thirty founded in 2015. The StorIQ in-store activity management platform is a valuable addition to Cegid’s retail portfolio, thereby bolstering its position as leader in retail POS solutions in France and worldwide.
StorIQ is particularly suitable for retailers with between 50 and 2,000 stores and already boasts around fifty clients including top brands such as Hugo Boss, Clarks, Douglas, Marks & Spencer International, Mountain Warehouse and Nespresso, some of which have deployed its solutions across the globe. StorIQ currently supports over 11,000 stores in more than 50 countries.
The StorIQ platform streamlines store activity planning and boosts productivity. The solution includes several modules:
- Task management and store communication: clear communication and prioritised tasks enable store managers to deliver brand standards and the expected in-store customer experience;
- Compliance: store visit reports, checklists, photo consolidation and associated reporting gives retail management teams real time visibility into store standards;
- Team Engagement: mobile learning (LMS), knowledge base and newsfeeds build employee engagement and support retention;
- Activity Planning: streamlines planning and communication for trading events and other in-store operational activity.
With 1,000 retailers running Cegid retail solutions in 75 countries, i.e. 75,000 connected stores, Cegid is helping speciality retailers and luxury brands transition to digital so as to better manage their omnichannel retail business, never miss a sale and tap into customer potential. The Cegid Retail unified commerce platform makes it possible to deliver an outstanding tailor-made shopping experience in stores worldwide. Thanks to StorIQ, the platform will now be able to cover all aspects of POS management.
StorIQ is an innovative solution built specifically for retail, and this acquisition cements Cegid’s expertise in all aspects of store operations - and further consolidates its international footprint. In addition, by improving employee experience in specialist retail, Cegid is securing its leadership in talent management.
“More than ever, the future of bricks-and-mortar stores will depend on the ability of retailers to accelerate and adapt so as to offer outstanding customer experiences as well as innovative and convenient services - while simplifying and monitoring in-store team task management. By capitalising on the current offerings of Cegid and StorIQ, brands and retailers will be able to offer an exceptional unified shopping experience across their entire store network while tapping into new sales opportunities ,” explains Cegid CEO Pascal Houillon. “Our current and future customers will be able to benefit from the optimised POS activity management offered by StorIQ paving their way to success . That’s what Retail the New Way is all about.”
StorIQ co-founder and Managing Director Amy Bastow and all the company staff will be joining the Cegid Retail Business Unit headed by Nathalie Echinard.
About StorIQ
StorIQ is a neat and intuitive retail operations app that saves time and makes life easier for store teams and retail management teams. StorIQ streamlines communications and task management, helping store teams to deliver brilliant brand standards, and retail leaders to make sure their stores get every detail right every day – maximising the value of the store estate. StorIQ is the easiest retail operations app to implement, with the most retail-specific feature set, and a world-class aftercare programme that ensures StorIQ delivers outstanding long term engagement.
StorIQ supports 11,000 stores in 55 countries, and our customers include global brands and local specialists across all sectors.
Founded in 2015, the company has around 30 employees and is based in London.
For more information: https://www.storiq.net/
About Cegid
Cegid is a leading provider of cloud business management solutions for finance (treasury, tax, ERP), human resources (payroll, talent management), CPAs, retail and entrepreneurial sectors. With a solid full cloud business model, Cegid provides long term commitment to its customers, superior and distinctive experiences and helps companies of all sizes accelerate their digital business transformation, locally and worldwide. Cegid combines a forward looking and pragmatic approach of the business with strong capacity to innovate, an in-depth expertise in new technologies and a unique understanding of regulations and compliance. In today’s rapidly changing world, Cegid makes more possible by helping customers unleash their potential thanks to innovative and purposeful business solutions.
Bolstered by its strong international ambition and reach, Cegid has 3,600 employees and sells its solutions in 130 countries. Cegid reported annual revenues of €632 million (December 31 2021). Pascal Houillon has been the CEO since March 2017.
For more information: www.cegid.com/en
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005087/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
